Drugs / XC221
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05295121 | Feb 2022 | — | Valenta Pharm JSC | Completed | No outcome recorded |
| Phase 1 | NCT03459391 | May → Sep 2017 | influenza | PHARMENTERPRISES LLC | Completed | No outcome recorded |
| Phase 23 trials · 1 missed | ||||||
| Phase 2 | NCT05030324 | Oct 2021 → May 2022 | influenza | Valenta Pharm JSC | Completed | No outcome recorded |
| Phase 2 | NCT03830905 | Jan → Jul 2019 | influenza | PHARMENTERPRISES LLC | Completed | No outcome recorded |
| Phase 2 | NCT03455491 | Feb → Jun 2018 | influenza | PHARMENTERPRISES LLC | Completed | Missed primary |
| Phase 33 trials | ||||||
| Phase 3 | NCT05544916 | Aug 2022 → Feb 2023 | influenza | Valenta Pharm JSC | Completed | No outcome recorded |
| Phase 3 | NCT04940182 | Jun 2021 → Aug 2022 | COVID-19 | RSV Therapeutics LLC | Completed | No outcome recorded |
| Phase 3 | NCT04487574 | Jul → Oct 2020 | COVID-19 | RSV Therapeutics LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XC221 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04940182 ↗ |
| Route | Oral | “XC221 100 mg orally.” NCT03455491 ↗ |